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Towards gene- and gender-based risk
estimates in Lynch syndrome; age-specific
incidences for 13 extra-colorectal cancer
types
Christina Therkildsen*,1, Steen Ladelund1, Lars Smith-Hansen1, Lars Joachim Lindberg1 and Mef Nilbert1,2
1HNPCC Register, Clinical Research Centre, Copenhagen University Hospital, Hvidovre, Denmark and 2Institute of Clinical
Sciences, Division of Oncology and Pathology, Lund University, Lund, Sweden
Background: In Lynch syndrome, inherited mismatch repair (MMR) defects predispose to colorectal cancer and to a wide
spectrum of extra-colorectal tumours. Utilising a cohort study design, we aimed to determine the risk of extra-colorectal cancer
and to identify yet unrecognised tumour types.
Methods: Data from 1624 Lynch syndrome mutation carriers in the Danish hereditary non-polyposis colorectal cancer register
were used to estimate the sex- and age-specific incidence rate ratios (IRRs) for 30 extra-colorectal malignancies with comparison
to the general population.
Results: Significantly increased IRRs were identified for 13 cancer types with differences related to gender, age and disease-
predisposing gene. The different cancer types showed variable peak age incidence rates (IRs) with the highest IRs for ovarian
cancer at age 30–49 years, for endometrial cancer, breast cancer, renal cell cancer and brain tumours at age 50–69 years, and for
urothelial cancer, small bowel cancer, gastric cancer, pancreatic cancer and skin tumours after age 70.
Conclusions: The broad spectrum of tumour types that develop at an increased incidence defines Lynch syndrome as a multi-
tumour syndrome. The variable incidences in relation to age, gender and gene suggest a need for individualised surveillance.
Lynch syndrome is caused by mutations in the mismatch repair
(MMR) genesMLH1,MSH2,MSH6 and PMS2, and represents one
of the most common hereditary cancer syndromes (de la Chapelle,
2005). The MMR deficiency genotype is associated with a 58–75%
life-time risk of cancer with frequent observations of synchronous/
metachronous tumour development (Giardiello et al, 2014; Moller
et al, 2015). Colorectal cancer and endometrial cancer predominate
with estimated cumulative risks of 10–74% and 15–71%,
respectively (Lu and Daniels, 2013; Vasen et al, 2013; Giardiello
et al, 2014; Moller et al, 2015). Cancer of the ovaries, stomach,
hepatobiliary tract, small bowel, brain and skin have been shown to
develop at an increased incidence in Lynch syndrome, whereas the
role of, for example, breast cancer, prostate cancer, pancreatic
cancer and sarcoma remains uncertain with inconclusive risk
estimates (Barrow et al, 2009; Kastrinos et al, 2009; Jensen et al,
2010; Urso et al, 2012; Lu and Daniels, 2013; Harkness et al, 2015;
Dominguez-Valentin et al, 2016).
Genotype–phenotype correlations have been described in Lynch
syndrome with a higher risk for urothelial cancer, skin tumours
and brain tumours in MSH2 mutation carriers, an increased risk
for gynaecological cancer in MSH6 mutation carriers, a higher risk
for breast cancer in MLH1 mutation carriers and a lower risk for
colorectal cancer in individuals with mutations in MSH6 and in
PMS2 (Plaschke et al, 2004; Barrow et al, 2009; Harkness et al,
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2015; Joost et al, 2015; Moller et al, 2015; Therkildsen et al, 2015).
Increasing evidence suggests that cancer risk and tumour spectrum
are influenced also by sex, genetic modifiers, obesity and life-style
factors such as physical activity, smoking and diet (Watson et al,
2008a; Barrow et al, 2009; van Duijnhoven et al, 2013; Movahedi
et al, 2015).
With the aim to determine the risk of extra-colorectal cancer
and to identify yet unrecognised tumour types in Lynch syndrome,
we determined the incidence rate ratios (IRRs) for 30 cancer types
in a cohort study design, including 1624 eligible mutation carriers
from the national Lynch syndrome cohort with comparison to a
population-based cohort from Denmark.
MATERIALS AND METHODS
The Danish hereditary non-polyposis colorectal cancer (HNPCC)
register contains more than 6000 families with suspected or
verified hereditary colorectal cancer reported to the register by
genetic counsellors, surgeons, pathologists and genetic diagnostic
laboratories’ report. Families have been included based on family
history of colorectal or endometrial cancer, or the demonstration
of MMR defects based on routine reflex MMR testing of colorectal
cancer. The Danish HNPCC register back-tracks and identifies all
family members regardless of cancer history and subclassifies
families according to genotypic and phenotypic features (Lindberg
et al, 2016). Irrespective of family history, individuals/families with
disease-predisposing MMR gene (MLH1, MSH2, MSH6, PMS2 or
EPCAM) mutations (classes 4–5 according to IARC system) are
defined as Lynch syndrome (Thompson et al, 2014). All family
members, also non-carriers, are contained in the register, which is
allowed to contact at-risk individuals by mail to ensure informa-
tion and offer genetic diagnostics. The study was granted
acceptance from the Danish Data Protection Agency. According
Danish regulations, anonymised registry studies are not subject to
ethical review.
Patient selection and data processing. All proven or obligate
MMR gene mutation carriers from the HNPCC register were
eligible for the study and are referred to as the Lynch syndrome
cohort. Family data and genetic test results were collected from the
HNPCC register. Data on primary extra-colorectal cancer
diagnoses were obtained from the population-based Danish Cancer
Registry, which is based on mandatory reporting from pathologists
and clinicians throughout the country. All diagnoses were verified
by pathological reports or medical reports. Benign tumours,
carcinoma in situ/dysplasia, basal cell carcinomas of the skin and
metastases from other primary tumours were excluded. Person
years at risk were determined as the period from date of birth to
date of diagnosis of any kind of cancer or date of death, whichever
came first. Patients with a primary and a secondary cancer in
different organs were, unless clinically regarded as metastases,
classified as metachronous cancers and were allowed to contribute
to the respective incidence estimates. Vital status was extracted
from the Danish Civil Registration System.
The population-based cohort included data from the Nordcan
database on age-specific cancer events and person years at risk in
the Danish background population with data completeness in the
time period 1 January 1978 to 31 December 2013 (Engel et al,
2016). These data were stratified according to year, sex, age and
disease. Double registrations were not allowed and cancer events
and person years at risk in the Lynch syndrome cohort were
subtracted from the population-based data in the Nordcan
database. Lynch syndrome-associated cancers were matched to
categories from the Nordcan database. Of the 36 cancer groups
specified in the Nordcan database, Lynch syndrome cancer
diagnoses were stratified into 30 distinct extra-colorectal cancer
subgroups. Motivated by the focus on extra-colorectal cancer, data
on colon cancer and rectal cancer (including anal cancer that could
not be distinguished from rectal cancer in the Nordcan database)
were excluded. Furthermore, unspecified cancer types and rare
diagnoses that were pooled in the Nordcan database were excluded.
For sarcoma, the analyses were restricted to 7 cases as the Nordcan
database classified 17 sarcomas from the Lynch syndrome cohort
according to organ rather than histotype. Patient selection for the
Lynch syndrome cohort is described in Supplementary Figure 1.
The study was designed to minimise ascertainment bias through
use of data from the national Danish Cancer register. In addition,
reflex testing for MMR defective colorectal cancer independent of
family history was on a national basis introduced more than 10
years ago. Further, we performed a subgroup analysis of cancers
diagnosed after the initiation of surveillance in the family, which
thus excluded diagnoses and corresponding person years at risk
before this date (Supplementary Figure 1).
Statistical analyses. Person years at risk and cancer events in the
Lynch syndrome cohort and in the population-based Nordcan
cohort were stratified by age, sex and year of diagnosis and
aggregated into four age groups (0–29, 30–49, 50–69 and 70 years
or above) using the %STRATIFY SAS macro, which removes
individuals from the at-risk group if cancer is diagnosed within the
study period, and SAS software, version 9.4 (SAS Institute Inc.,
Cary, NC, USA) (Rostgaard, 2008). For the entire study cohort,
time at risk was determined as the time from study entry
(1 January 1978) or date of birth, whichever occurred latest to
study exit (31 December 2013) or date of death, whichever
occurred first. For the subgroup in surveillance, study entry dates
were defined as the date of first colonoscopic surveillance in the
family. Relatedness was handled as conditioned independent given
the MMR mutation, age, year of diagnosis and sex.
Stratified and aggregated data were transferred into R i386 3.1.0
(R: A Language and Environment for Statistical Computing, 2011).
Incidence rates (IRs) were calculated as the number of events
divided by person years at risk in each age group. Incidence rate
ratios were calculated as the ratio between the IRs in Lynch
syndrome and in the background population. Exact conditional
95% confidence intervals (CIs) and P-values were calculated using
the exact Poisson test. Separate analyses stratified by age group and
cancer type (and MMR gene mutation and sex for cancer types
with more than 15 events) were performed to assess IRs in relation
to genotype and phenotype. Significance levels were corrected for
multiple testing using Bonferroni correction with the null
hypothesis that Lynch syndrome mutation carriers do not have
an increased risk of each specific cancer subtype (with significance
set at Po0.0125). All P-values were two-sided.
Pooled IRs for extra-colorectal cancer were based on sum-
marised IRs for all cancer types within each age group and
asymptotic 95% CIs were calculated following the central limit
theorem of Poisson distributions.
RESULTS
Extra-colorectal cancers. The total Lynch syndrome cohort
comprised 1624 mutation carriers from 365 Lynch syndrome
families that contributed with 51 237 person years at risk. The
cohort included families with pathogenic variants in MLH1
(n¼ 94), MSH2 (n¼ 155, including one family with an EPCAM
mutation), MSH6 (n¼ 98) and PMS2 (n¼ 18; Table 1). During the
study period, 762 mutation carriers developed 1095 malignancies
that included 535 colorectal cancers and 560 extra-colorectal
cancers. The extra-colorectal malignancies represented 30 distinct
cancer types with the most common being endometrial cancer
(n¼ 163), urothelial cancer (n¼ 75), breast cancer (n¼ 47), non-
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melanoma skin tumours (n¼ 39) and ovarian cancer (n¼ 30;
Supplementary Table 1).
Overall IRRs for extra-colorectal cancer. The IRs of any type of
extra-colorectal cancer were separately estimated in men and
women from the Lynch syndrome cohort compared to population-
based cohorts. Significantly increased IRRs were identified in the
Lynch syndrome cohort for any extra-colorectal malignancy for all
age groups and both sexes compared to the background population
(Figure 1A). Within the Lynch syndrome cohort, women had
significantly higher IRRs than men with an IRR of 3.1 at 30–49
years and an IRR of 1.8 at 50–69 years (Figure 1A).
The incidence of extra-colorectal cancer was also studied in
relation to disease-predisposing MMR gene. In PMS2 mutation
carriers, no increased IR for extra-colorectal cancer was demon-
strated and as only three extra-colorectal cancers (one endometrial
cancer, one gastric cancer and one prostate cancer) developed,
PMS2 was omitted from further analyses. The median ages at onset
for any extra-colorectal cancer were 53, 53 and 55 years for MLH1,
MSH2 and MSH6 mutation carriers, respectively. Higher IRRs
were found for MSH2 mutations compared to MSH6 mutations
with significant differences from age 30 (IRR¼ 2.0 at age 30–49
years, 1.6 at age 50–69 years and 2.4 at age 70 and above;
Figure 1B).
Incidence rates for specific cancer types. Of the 30 cancer types
represented in the Lynch syndrome cohort, significantly increased
IRRs in at least one age group were demonstrated for 13 diagnoses.
Of these, endometrial cancer, ovarian cancer, urothelial cancer,
gastric cancer, brain tumours, non-melanoma skin tumours and
cancer of the small bowel have been linked to Lynch syndrome,
whereas the role of breast cancer, prostate cancer, lung cancer,
kidney cancer, pancreatic cancer and eye tumours in Lynch
syndrome is uncertain (Figure 2; Table 2; Supplementary Table 2).
Strikingly different peak incidence ages were identified for the
different tumour types (Figure 2). Ovarian cancer and eye tumours
had the highest IRs in the age group 30–49 years with an IR of
252.7 (95% CI¼ 163.5–373.0) for ovarian cancer and an IR of 10.7
(95% CI¼ 1.3–38.6) for eye tumours (Supplementary Table 2).
Though the absolute numbers were low, Lynch syndrome mutation
carriers showed a 14.5-fold increased IR for eye tumours, including
uveal malignant melanoma, compared to the population-based
cohort. Endometrial cancer, breast cancer and brain tumours
showed peak IRs in the age group 50–69 years; endometrial cancer
had an IR of 1686.1 (95% CI¼ 1355.8–2072.5), breast cancer an IR
of 530.3 (95% CI¼ 349.5–771.5) and brain tumours an IR of 92.5
(95% CI¼ 42.3–175.7; Supplementary Table 2). Compared to the
general population, the overall highest IRRs applied to endometrial
cancer in the age group 30–49 years with a 133-fold increased IR
(95% CI¼ 103.3–168.6, Po0.0001; Table 2). For other tumour
types, that is, non-melanoma skin tumours, urothelial cancer, small
bowel cancer, gastric cancer and pancreatic cancer the IR increased
with age with the highest risk above age 70 (Figure 2; Table 2).
Urothelial cancer showed significantly increased IRRs in all age
groups, while non-melanoma skin tumours, small bowel cancer
and gastric cancer developed at increased IRRs from age 30
compared to the population-based cohort. Pancreatic cancer
showed significantly increased IRR from age 70 (IRR¼ 3.7, 95%
CI¼ 1.2–8.7, P¼ 0.01182).
An early age at onset was observed for lung cancer, kidney
cancer and prostate cancer with significantly increased IRRs in the
age groups 30–49 and 50–69 years, respectively (Figure 2; Table 2).
Compared to the population-based cohort, Lynch syndrome
mutation carriers had a 4.7-fold increased IR (95% CI¼ 2.3–8.7,
Po0.0001) of kidney cancer at the age 50–69 years and a 3.5-fold
increased IR (95% CI¼ 1.4–7.2, P¼ 0.00471) for early-onset lung
cancer at the age 30–49 years. The 23 lung cancers developed at
median 53 years and included 11 non-small-cell lung cancers, 8
small-cell lung cancers, 1 neuroendocrine tumour and 3 with
unclassified subtype. The IR of prostate cancer was 2.5-fold
Table 1.MMR gene distribution in the entire Lynch syndrome
cohort and the subgroup in surveillance
Entire Lynch
syndrome cohort
Lynch syndrome
cohort in surveillance
Individuals
Extra-
colonic
cancers Individuals
Extra-
colonic
cancers
n (%) n (%) n (%) n (%)
Cohort size 1624 560 1336 222
Unaffected 862 (53.1) — 1028 (76.9) —
MMR gene
mutation
MLH1 443 (27.3) 128 (22.9) 370 (27.7) 60 (27.0)
MSH2/EPCAM 701 (43.2) 289 (51.6) 616 (46.1) 129 (58.1)
MSH6 419 (25.8) 140 (25.0) 317 (23.7) 33 (14.9)
PMS2 61 (3.8) 3 (0.5) 33 (2.5) 0 (0)
Sex, men 754 (46.4) 178 (31.8) 631 (47.2) 91 (41.0)
Abbreviation: MMR¼mismatch repair.
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Figure 1. Incidence rates for all extra-colorectal cancer in Lynch syndrome. Age-dependent incidence rates and 95% confidence intervals for all
extra-colorectal cancers were estimated in Lynch syndrome mutation carriers in relation to (A) gender or (B) mutated MMR gene. (A) Solid lines,
Lynch syndrome; dotted lines, population-based cohort; black lines, men; grey lines, women; shaded areas¼ 95% confidence intervals. (B) Blue,
MLH1; red, MSH2; green, MSH6; purple¼PMS2; shaded areas¼95% confidence intervals.
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increased (95% CI¼ 1.4–4.1) in male MMR mutation carriers at
the age of 50–69 years compared to the population-based cohort.
Though 17 sarcomas developed at a median age of 48.5 years,
separate sarcoma analyses could only be performed based on 1
bone sarcoma and 6 connective tissue sarcomas. The latter showed
a nonsignificant IRR of 6.3 (95% CI¼ 1.3–18.4, P¼ 0.01261) at age
50–69 years compared to the population-based cohort.
Gene- and sex-specific IRs. Cancer type-specific IRs were in
subsets with minimum 15 events estimated according to the
disease-predisposing MMR genes. Significantly increased IRRs
were identified inMSH2 mutation carriers compared toMLH1 and
MSH6 for four cancer types, that is, endometrial cancer, urothelial
cancer, non-melanoma skin tumours and ovarian cancer, with
particular increased incidence in the younger age groups
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Figure 2. Cancer types with significantly increased incidence rate ratios in the Lynch syndrome cohort. Age-dependent incidence rates and 95%
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Table 2. Age-dependent incidence rate ratios for extra-colonic cancer in Lynch syndrome mutation carriers
Lynch syndrome vs population-based cohort
Cancer Age groups IRR 95% CI lower 95% CI upper P-values
Endometrial cancer (n¼ 163) 0–29 0 0 278.7 1
30–49 133.0 96.2 178.9 o0.0001
50–69 27.4 20.7 35.5 o0.0001
70þ 4.6 0.8 14.1 0.01218
Urothelial cancer (n¼ 75) 0–29 34.2 2.0 154.7 0.00165
30–49 8.3 2.8 18.9 o0.0001
50–69 8.2 5.5 11.7 o0.0001
70þ 7.1 3.6 12.5 o0.0001
Breast cancer (n¼ 47) 0–29 6.7 0.0 48.2 0.13853
30–49 1.7 0.8 3.1 0.05996
50–69 1.9 1.1 3.0 0.00224
70þ 1.2 0.2 3.6 0.59032
Non-melanoma skin tumours (n¼ 39) 0–29 0 0 89.2 1
30–49 17.8 6.4 38.9 o0.0001
50–69 11.0 6.0 18.3 o0.0001
70þ 4.2 1.4 9.5 0.00086
Ovarian cancer (n¼ 30) 0–29 0 0 41.9 1
30–49 24.4 13.9 39.6 o0.0001
50–69 2.0 0.5 5.6 0.10343
70þ 0 0 7.4 1
Prostate cancer (n¼ 24) 0–29 0 0 14 505.7 1
30–49 0 0 37.2 1
50–69 2.5 1.3 4.5 0.00059
70þ 1.5 0.5 3.7 0.23773
Small bowel cancer (n¼ 19) 0–29 0 0 737.4 1
30–49 107.3 35.7 245.7 o0.0001
50–69 32.3 11.6 70.4 o0.0001
70þ 18.1 1.1 81.6 0.00567
Lung cancer (n¼ 23) 0–29 0 0 136.8 1
30–49 3.5 1.1 8.3 0.00471
50–69 1.0 0.4 1.8 1
70þ 0.4 0.0 1.6 0.19510
Gastric cancer (n¼21) 0–29 0 0 226.0 1
30–49 8.0 1.4 24.7 0.00172
50–69 6.1 2.6 12.1 o0.0001
70þ 5.2 1.2 14.4 0.00304
Brain tumours (n¼ 21) 0–29 1.8 0.1 8.0 0.30849
30–49 3.6 1.4 7.6 0.00061
50–69 2.6 0.9 5.6 0.00984
70þ 0 0 5.6 1
Kidney cancer (n¼ 13) 0–29 0 0 58.9 1
30–49 1.7 0.0 11.9 0.45410
50–69 4.7 1.8 9.9 0.00007
70þ 2.6 0.2 11.8 0.17865
Pancreatic cancer (n¼13) 0–29 0 0 573.5 1
30–49 2.3 0.0 16.7 0.34888
50–69 2.8 0.8 6.6 0.01541
70þ 3.7 0.9 10.4 0.01182
Eye tumours (n¼3) 0–29 0 0 85.5 1
30–49 14.5 0.8 65.4 0.00869
50–69 4.0 0.0 28.9 0.21992
70þ 0 0 68.0 1
Abbreviations: CI¼ confidence intervals; IRR¼ incidence rate ratio. Incidence rates and 95% CI for the Lynch syndrome cohort and the population-based cohort are shown in Supplementary
Table 2. Bold P values indicate significance following Bonferroni correction.
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(Figure 3). In the age group 30–49 years, the IRR for endometrial
cancer was 2.3 (95% CI¼ 1.2–4.7, P¼ 0.0107) forMSH2 compared
to MSH6, and the IRR for ovarian cancer was 4.5 (95% CI¼ 1.3–
23.6, P¼ 0.0077) for MSH2 compared to MLH1. In the age group
50–69 years, the IRR for urothelial cancer was 4.0 (95% CI¼ 1.7–
11.5, P¼ 0.0006) for MSH2 compared to MLH1 and 5.1 (95%
CI¼ 2.1–14.7, P¼ 0.00003) compared to MSH6, and for non-
melanoma skin cancer the IRR was 13.3 (95% CI¼ 2.1–558.3,
P¼ 0.00084) for MSH2 compared to MSH6. No significant
difference was found in relation to the mutated MMR gene for
gastric cancer, small bowel cancer, breast cancer, lung cancer,
prostate cancer and brain tumours.
No difference in relation to sex was observed for urothelial
cancer, gastric cancer, small bowel cancer, lung cancer or brain
tumours, whereas non-melanoma skin tumours showed a higher
IRR for male compared to female MMR mutation carriers above
age 70 with an IRR of 11.6 (95% CI¼ 1.5–524.5, P¼ 0.0056).
Incidence rates for ascertained tumour types. To correct for
potential ascertainment bias, we performed separate subgroup
In
ci
de
nc
e 
ra
te
 p
er
 1
00
00
0 
ye
ar
s
In
ci
de
nc
e 
ra
te
 p
er
 1
00
00
0 
ye
a
rs
In
ci
de
nc
e 
ra
te
 p
er
 1
00
00
0 
ye
a
rs
In
ci
de
nc
e 
ra
te
 p
er
 1
00
00
0 
ye
a
rs
2000
1500
1000
500
0
Endometrial cancer Ovarian cancer
Breast cancer
0–29 30–49 50–69 70+
Age groups
0–29 30–49 50–69 70+
Age groups
0–29 30–49 50–69 70+
Age groups
0–29 30–49 50–69 70+
Age groups
0–29 30–49 50–69 70+
Age groups
0–29 30–49 50–69 70+
Age groups
0–29 30–49 50–69 70+
Age groups
0–29 30–49 50–69 70+
Age groups
0–29 30–49 50–69 70+
Age groups
0–29 30–49 50–69 70+
Age groups
400
300
200
100
0 0
2000
1500
1000
500
Urothelial cancer
Brain tumourNon-melanoma skin tumour
0
600
400
200
800
600
400
200
0
100
50
0
Lung cancer Prostate cancer Small bowel cancer
Gastric cancer
250
200
150
100
50
0
1500
1000
500
0
300
200
100
0
500
400
300
200
100
0
Figure 3. Incidence rates for the 10 most frequent cancer types in Lynch syndrome. Age-dependent incidence rates were calculated separately
by the mutated MMR genes MLH1 (blue), MSH2 (red) and MSH6 (green) for cancer types with more than 15 events.
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analysis in 1336 mutation carriers from 309 families (including
12 773 person years at risk) with time at risk restricted to the time
after initiation of surveillance in the family (Supplementary
Figure 1). The analysis encompassed 222 extra-colorectal cancers,
including 47 endometrial cancers, 35 urothelial cancers, 23 ovarian
cancer, 13 gastric cancer, 10 brain tumours and 8 cancers of the
small bowel (Table 1; Supplementary Table 1). A limited number
of individuals in the oldest age group restricted power above age
70, whereas robust risk estimates were obtained in the age groups
30–49 and 50–69 years. In here, endometrial cancer showed IRRs
of 121.5 (95% CI¼ 69.4–197.5, Po0.0001) and 24.7 (95%
CI¼ 16.4–35.7, Po0.0001), urothelial cancer had IRRs of 11.3
(95% CI¼ 2.3–33.1, P¼ 0.00254) and 10.9 (95% CI¼ 6.9–16.4,
Po0.0001) and cancer of the small bowel had IRRs of 224.6 (95%
CI¼ 79.2–573.1, Po0.0001) and 29.4 (95% CI¼ 6.1–85.8,
P¼ 0.00017; Figure 4; Supplementary Table 3). Significantly
increased IRRs were also identified for breast cancer, non-
melanoma skin tumours, ovarian cancer, gastric cancer, brain
tumours and pancreatic cancer (Supplementary Table 3).
DISCUSSION
In Lynch syndrome, surveillance and preventive measures
effectively reduce morbidity and mortality from colorectal cancer
and prolong life expectancy, which in turn increase the time at risk
for other syndrome-associated tumour types (Jarvinen et al, 2009;
Lu and Daniels, 2013). Indeed, 61% of cancer-related deaths in
Lynch syndrome mutation carriers have been estimated to be
caused by cancer types other than colorectal and endometrial
cancer (Pylvanainen et al, 2012). In the Danish Lynch syndrome
cohort, cancer has been diagnosed in 47% of the mutation carriers
with 51% being extra-colorectal cancers. We demonstrate sig-
nificantly increased IRs for 13 cancer types and thereby further
define Lynch syndrome as a multi-tumour syndrome. Increased
IRs applied from age 30 (Figure 1). In the age group 30–69 years,
female mutation carriers had a higher IR than male mutation
carriers due to early-onset endometrial cancer, ovarian cancer and
breast cancer (Figure 2). The overall IRR of extra-colorectal cancer
was highest in MSH2 mutation carriers, which was largely
explained by urothelial cancer, endometrial cancer, ovarian cancer
and skin tumours (Figures 1 and 2).
An increased risk of gynaecologic cancer, that is, endometrial
cancer and ovarian cancer, has been defined in Lynch syndrome
(Lu and Daniels, 2013; Moller et al, 2015). Our findings are in
accordance with previous studies in Lynch syndrome and provide
additional age-specific IRRs (Engel et al, 2012; Win et al, 2012).
Endometrial cancer showed the highest IRR relative to the general
population at age 30–49 (IRR¼ 133), whereas the highest IR
applied to the age group 50–69 (IR¼ 1686.1). The increased IR for
endometrial cancer applied to all MMR genes though the IRR for
MSH2 at age 30–49 years was significantly higher compared to
MSH6 and MLH1, which is in agreement with studies showing
increased risk in MSH2 mutation carriers (Moller et al, 2015). The
results remained stable in the subgroup analysis with a 122-fold
increased IR in the age group 30–49 years. The high risk for
endometrial cancer is generally accepted to motivate surveillance
though the benefit is uncertain, partly because these cancers
present with gynaecologic bleedings in early stages (Lu and
Daniels, 2013; Syngal et al, 2015; Moller et al, 2015). Ovarian
cancer showed an IRR of 24.4 with a distinct peak at age 30–49.
The early onset and the narrow age span of Lynch syndrome-
associated ovarian cancer challenges recommendations for surveil-
lance and/or prophylactic surgery (Helder-Woolderink et al, 2016).
Though the absolute risk of ovarian cancer has been estimated to
be 1–4% at age 40 by Moller et al, 2015, the relative risk compared
to the background population still remain high especially in the
young age groups.
The increased IRRs identified for urothelial cancer, cancer
of the small bowel and gastric cancer are comparable with reports
from Win et al (2012) and Engel et al (2012), and were not
influenced by sex. The estimates remained stable in the subset
analyses with significantly increased IRRs between ages 30
and 69 (Supplementary Table 3). The incidence of urothelial
cancer in MSH2 compared to MLH1 and MSH6 in the age group
50–69 years strengthens the links between MSH2 and urothelial
cancer and suggests that urinary surveillance is particularly
relevant in MSH2 mutation carriers (Watson et al, 2008b; Aarnio
et al, 2012). Gastric cancer and cancer of the small bowel have
lifetime riskso10% and gastrointestinal endoscopic surveillance is
therefore not broadly recommended, though Helicobacter pylori
screening and potential eradication is relevant (Win et al, 2012;
Vasen et al, 2013).
The role of breast cancer in Lynch syndrome is controversial
(Watson et al, 2008b; da Silva et al, 2010; Harkness et al, 2015).
The IRR for breast cancer of 1.9 identified in our series is
comparable to the standardised IRRs (SIR) estimated in recent
reports and did not show any impact in relation to MMR gene
(Engel et al, 2012; Win et al, 2012; Harkness et al, 2015). As the
risk increase is at most doubled and most countries offer
population screening for breast cancer, current data do not call
for additional preventive measures.
40020002000
In
ci
de
nc
e 
ra
te
 p
er
 1
00
00
0 
ye
ar
s
1500
1000
500
0
1500
1000
500
0
0–29 30–49 50–69 70+0–29 30–49 50–69 70+
Small bowel cancerUrothelial cancerEndometrial cancer
300
200
100
0
0–29 30–49
Age groupsAge groupsAge groups
50–69 70+
Figure 4. Incidence rates for ascertained tumour types in the entire Lynch syndrome cohort and a subgroup of the cohort excluding cancer
events before the first colonoscopic surveillance in the family. Age-dependent incidence rates and 95% confidence intervals are shown for the
entire Lynch syndrome cohort (black line) and the subgroup herein (grey line) compared to the general population (dotted line) for endometrial
cancer, urothelial cancer and small bowel cancer. Shaded areas, 95% confidence intervals.
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We identified an increased IRR of non-melanoma skin tumours
from age 30 with significantly higher incidence in MSH2 mutation
carriers compared to MSH6 mutation carriers. Muir–Torre
syndrome refers to a variant of Lynch syndrome with development
of multiple skin tumours, particularly sebaceous adenomas and
carcinomas, and a link to MSH2 mutations (South et al, 2008).
Though the overall life-time risk of skin tumours in Lynch
syndrome families would not call for intensive surveillance
programmes, these results argue for increased awareness of skin
cancer especially in MSH2 mutation carriers.
Increased IRRs were identified for a number of tumour types
that have in case reports and smaller studies been suggested to
develop as part of Lynch syndrome, that is, kidney cancer, lung
cancer, pancreatic cancer and prostate cancer (Figure 2; Table 2)
(Nolan et al, 2009; Kastrinos et al, 2009; Ryan et al, 2014;
Therkildsen et al, 2016). Though MMR deficiency and micro-
satellite instability are rarely observed in kidney cancers a link
between kidney cancer and Lynch syndrome has been suggested
(Aarnio et al, 1999; Therkildsen et al, 2016). Pancreatic cancer
developed at an increased IRR of 3.7 from age 70, which is
somewhat lower than a relative risk of 8.6 reported by Kastrinos
et al, 2009. Several studies have suggested an increased risk of
prostate cancer in Lynch syndrome and our identification of an
IRR of 2.5 is within the range of previously published SIR of 2.1–
2.5 (Engel et al, 2012; Win et al, 2012; Raymond et al, 2013; Ryan
et al, 2014). Data on lung cancer in Lynch syndrome are scarce,
and our study is the first to suggest a significantly increased IRR of
3.5 at an early age (30–49 years) (Pande et al, 2012; Warth et al,
2016). Eye tumours have not previously been described in Lynch
syndrome mutation carriers and notably two of three eye tumours
from this study were malignant melanomas. Though the IRRs of
these rare tumour types may be increased at specific age groups,
the absolute risk is limited (o5%) and does not motivate
surveillance.
Extra-colorectal tumours in Lynch syndrome showed distinct
peak incidence patterns (Figure 2). Ovarian cancer and eye
tumours showed the highest risk at young age (30–49 years).
Endometrial cancer, breast cancer, brain tumours and lung
cancer developed with the highest incidence in the age group
50–69 years. Urothelial cancer, small bowel cancer, gastric cancer,
kidney cancer, prostate cancer, pancreatic cancer and non-
melanoma skin tumours showed a continuously increasing IR
with age. Early age at onset characterises hereditary tumours and
the earlier onset of, for example, prostate cancer and lung cancer in
our series may suggest that these tumour types may develop at an
earlier age in individuals with Lynch syndrome (Hampel et al,
2005; Meyer et al, 2009; Joost et al, 2015; Helder-Woolderink
et al, 2016).
The size of our cohort allowed for subgroup analysis to correct
for ascertainment bias for the most frequently occurring cancer
types, that is, endometrial cancer, urinary tract cancer and cancer
of the small bowel (Figure 4). When the analyses were restricted to
cancers that developed after the initiation of colonoscopic
surveillance in the family, the results remained stable and thus
demonstrate robust IRR estimates without evidence from ascer-
tainment bias (Supplementary Table 3). Though the sample size in
the oldest age group was limited due to high mortality rates, the
peak age incidence pattern was consistent for endometrial cancer
and urothelial cancer, whereas a shift was identified for cancer of
the small bowel (Figure 4). Denmark has a long history of active
diagnostics of Lynch syndrome with national registers for
hereditary colorectal cancer, a national genetic network and reflex
testing for MMR defects in colorectal cancer diagnostics since
2007. Though, at present 53% of the Lynch syndrome cohort
remain without cancer, the estimated carrier frequency of 1:279
implies that a considerable fraction of the Lynch syndrome families
still remain undiagnosed (Win et al, 2016). The impact from
preventive interventions is estimated to be minimal based on use of
historic data and lack of demonstrated efficacy from surveillance or
chemoprevention for extra-colorectal cancer.
In summary, we identified increased IRRs for 13 extra-colorectal
cancer types in the Danish Lynch syndrome cohort relative to the
Danish background population. The very early-age peak incidences
for ovarian cancer and brain tumours and the increased IRRs for
urothelial cancer after age 50 and in MSH2 mutation carriers are
relevant to consider in future surveillance strategies in Lynch
syndrome. The broad tumour spectrum, the overall increased risk
for MSH2 mutation carriers, the distinct and variable incidence
patterns in relation to age, sex and cancer type are important to
recognise for clinicians, geneticists and counsellors and provide a
basis for targeted surveillance programmes.
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